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Brain-lung-thyroid syndrome (BLTS) is a rare disorder characterized by congenital hypothyroidism (CH), infant 
respiratory distress syndrome (IRDS) and benign hereditary chorea (BHC). BLTS is caused by mutations in the 
NKX2.1 gene. 
Objective 
We describe a patient with TD, respiratory disease and cerebral palsy and who has two heterozygous mutations in 
the PAX8 (p.E234K) and the NKX2.1 (p.A329GfsX108) genes. In vitro studies were performed to functionally 
characterize these mutations. 
Patient 
The 12 years-old boy was diagnosed to have congenital hypothyroidism (CH) at neonatal screening, with a serum 
TSH of 49.5 mU/L (N: 0.4-9) and a T4 of 3.76 µg/dl (N: 50-197). The thyroglobulin value was 3.18 ng/ml, N<55 
and hypoplastic thyroid in ultrasonography. After birth, he developed severe respiratory failure, seizures and an 
ischemic cerebral infarction. He was diagnosed with cerebral palsy and symptomatic epilepsy and developed a 
considerable psychomotor retardation. Currently he is euthyroid under L-thyroxine supplementation. His sister and 
the parents are healthy and euthyroid. 
Methods 
We introduced the two identified mutations into expression vectors and transiently transfected them into HeLa 
cells. In EMSA studies we tested for the DNA binding capability of the two mutated transcription factors. 
Results 
The PAX8 mutation was normally located to the nucleus and showed a normal transactivation of and normal 
binding to the known downstream targets. In contrast the NKX2.1 mutation did not show any transactivation 
ability due to the loss of the capability to bind to DNA. It remains to be elucidated whether the NKX2.1 mutation 
localizes to the nucleus. 
Conclusions 
The NKX2.1 mutation might be responsible for the phenotype observed in our patient. The synergistic effect is 
completely abolished by the NKX2.1 mutation when cells were co-transfected with the PAX8 expression 
constructs. 
